ArticleMolecular imaging and biology2018
Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Tumor-Associated Carbohydrate Antigen 19-9 (CA 19-9), a Promising Target for Antibody-Based Detection, Diagnosis, and Immunotherapy of Cancer.ChemMedChem · 2024Review
- Exploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer.ACS pharmacology & translational science · 2024Article
- EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.Molecular imaging and biology · 2022Article
- Molecular imaging of cellular immunotherapies in experimental and therapeutic settings.Cancer immunology, immunotherapy : CII · 2022Review
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
- The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- ImmunoPET Imaging of Pancreatic Tumors withMolecular imaging and biology · 2021Article
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- Review
- PET/CT Imaging with anJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.Inorganic chemistry · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.Molecular pharmaceutics · 2020Article
- ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeTumor-specific molecular imaging is an important tool for assessing disease burden and treatment response. CA19.9 is an important tumor-specific marker in several malignancies, including urothelial carcinoma. [ PROCEDURES: Surface expression of CA19.9 was confirmed in the human bladder cancer line HT 1197. The radioimmunoconjugate [
results[
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.